Connect with us

Press Release

China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China

Published

2 weeks ago

on

SHENZHEN, CHINA – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies.

 

Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.

 

According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand.

 

The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China.

 

With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

References:

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

 

  1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-c…
  2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association
  3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164
  4. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

AiBase Uses Cutting-Edge AI Technology to Transform Crypto Trading

Published

5 minutes ago

on

December 23, 2024

By

AiBase is hanging cryptocurrency trading by eliminating entry barriers.

California, United States, 23rd Dec 2024 – Ai Base is truly transforming crypto trading with its state-of-the-art technology, which provides traders with unmatched data analytics, strategic signals, and predictive insights that enable them to optimize earnings and remain ahead of market trends.

Smarter Trading with Advanced AI

AiBase analyzes enormous volumes of data across more than 75 indicators and factors by integrating sophisticated AI algorithms. This provides a thorough picture of market sentiment and trends and incorporates blockchain data, social media activity, project launch platforms, and market forums.

Predictive Knowledge for Upcoming Results

To estimate Bitcoin performance, AiBase creates predictive models by spotting intricate patterns and relationships. Traders can predict price movements and make confident decisions thanks to this forward-thinking technique.

AI-Powered Picking of Tokens and Useful Signals

AiBase uses its predictive models to choose high-potential tokens in addition to analysis. AI-generated trading signals that are actionable and customized for changing market conditions are sent to traders. By identifying the ideal entrance points, these signals maximize prospects for expansion and financial gain.

Proven Results with Big Wins

AiBase has demonstrated its ability to identify game-changing tokens early. Some of its notable successes include:

  • $brett: $5.7K to $1.94B market cap (34,035,000%)
  • $SHI: $6.5K to $1.12M market cap (17,200%)
  • $WORKIE: $2.1K to $2.84M market cap (1,335,000%)
  • $ROCKY: $33.2K to $14.68M market cap (44,200%)

These success stories reflect AiBase’s precision in identifying emerging opportunities that others might miss.

Key Features:

  • Minimal Entry Barrier: With as little as $10, begin trading.
  • Access a Wide Range of Markets: Exchange hundreds of meme coins and experiment with different tactics.
  • User-Friendly Design: A simple platform that is appropriate for both novice and experienced traders.
  • Real-Time Tools: Real-time data and insights are provided by integrated scanners and tools.
  • Mobile Compatibility: Using mobile devices to trade seamlessly while on the go.
  • VIP Access: Chances to dominate the market with unique insights on artificial intelligence.
  • Customization: Exceptionally fast updates and a fully customizable interface.

Encouraging Traders at Every Level

Accessibility and technology are connected by AiBase. The platform offers tools and techniques for traders of all skill levels and risk tolerances, regardless of experience level.

Embrace the Revolution in AI-Powered Trading

The bitcoin industry moves quickly, so timing and strategy are crucial. AiBase uses real-time signals, predictive modeling, and AI-powered insights to provide businesses with a competitive edge. Members have access to professional tactics, early notifications, and an expanding network of cryptocurrency aficionados.

About AiBase

AiBase is a cutting-edge platform that enables traders to optimize earnings and confidently traverse the ever-changing cryptocurrency market through the use of predictive models, real-time statistics, and practical tactics.

To learn more, visit: 

https://aibasebot.com/

https://aibasebot.xyz/

For the latest updates, follow AiBase on Social Media.

Twitter: https://x.com/aibasebot

Main TG: https://t.me/AiBaseVerify

Gitbook: https://aibase.gitbook.io/aibase

 

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact

Organization: AiBase Bot

Contact Person: L. Powell, Founder

Website: https://aibasebot.xyz

Email: Send Email

City: California

Country: United States

Release Id: 23122421844

The post AiBase Uses Cutting-Edge AI Technology to Transform Crypto Trading appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Inside the NBA Welcomes Mentalist Paul Draper for a Magical Night in Las Vegas

Published

1 hour ago

on

December 23, 2024

By

United States, 23rd Dec 2024 – This month, mentalist and entertainer Paul Draper brought his signature blend of magic and mind-reading to the set of Inside the NBA, leaving hosts Shaquille O’Neal, Ernie Johnson, Kenny Smith, and Charles Barkley stunned with amazement.

“That was Awesome!” exclaimed Shaquille O’Neal, with Ernie Johnson adding, “That is Unbelievable!” The excitement didn’t stop there, as Charles Barkley shouted, “Oh, My Goodness, WOW!” and Kenny Smith playfully reacted with, “Come On, Man!”

Show: https://youtu.be/xGHRVV0XjeM?si=v61xJOp0mtDb6Yi7

Appearing on the iconic Inside the NBA show was a career milestone and a true delight for Draper, whose performance created genuine moments of joy and wonder among the all-star hosts.

“Watching their reactions reminded me why I love what I do,” said Draper. “Magic has a unique way of bringing people together, sparking curiosity, and creating connections that last far beyond the moment.”

Whether on national television or at private corporate events, Paul Draper is dedicated to delivering unforgettable experiences that blend entertainment, inspiration, and teamwork. “Fans of Inside the NBA know the power of collaboration, quick thinking, and showmanship—qualities I strive to bring to every event I perform,” Draper shared. The authenticity of the interactions on set made this experience truly special. From the hosts’ playful banter to their genuine surprise, Draper’s magic proved that it can transcend settings and connect with anyone, anywhere.

For Booking Inquiries: Paul Draper Email: Paul@PaulDraper.com Website: https://PaulDraper.com

About Paul Draper

Paul Draper has been seen on History, A&E, HBO, Discovery, Hallmark, Travel, HGTV, and shows like Hell’s Kitchen, Pawn Stars, Mindfreak, and House Hunters. In Las Vegas, he has headlined showrooms for casinos including the Orleans Casino & Planet Hollywood and served as house magician for 7 years at the Venetian. Recently he has been working as a professor and distinguished lecturer at multiple universities while also performing shows at Disneyland and just returned this month from Europe performing and speaking at the United Nations in Geneva, Switzerland and at Cambridge University.

Poster images and photos: https://pauldraper.com/information-and-media/

Website: https://PaulDraper.com

Media Contact

Organization: Paul Draper

Contact Person: Paul Draper

Website: https://PaulDraper.com

Email: Send Email

Country: United States

Release Id: 23122421818

The post Inside the NBA Welcomes Mentalist Paul Draper for a Magical Night in Las Vegas appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

PRIVATE POLICE INTRODUCES EXCLUSIVE NFT COLLECTION ON OPENSEA.IO

Published

2 hours ago

on

December 23, 2024

By

PRIVATE POLICE , an innovative force in global security and international control, proudly announces the launch of its exclusive NFT Collection on the world’s leading digital asset marketplace, OpenSea.io

 

ABOUT THE COLLECTION

• Exclusivity: A limited number of unique NFTs, each symbolizing strength, prestige, and responsibility.

• Digital Legacy: Every NFT is a digital masterpiece, embodying the core principles of PRIVATE POLICE: honor, discipline, and innovation.

• Exclusive Rights: NFT owners will gain access to special privileges, including invitations to private events and projects organized by PRIVATE POLICE.

 

A GLOBAL VISION

 

This NFT collection marks a significant step towards integrating advanced blockchain technology with the legacy of PRIVATE POLICE, ensuring transparency, security, and global recognition in the digital realm.

 

Visit : https://opensea.io/luxpolice for more .

Media Contact

Organization: Private Police OF United Ukrainian Emirates

Contact Person: Private Police

Website: https://privatepolice.pp.ua

Email: Send Email

Country: Ukraine

Release Id: 23122421822

The post PRIVATE POLICE INTRODUCES EXCLUSIVE NFT COLLECTION ON OPENSEA.IO appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us